Grafil Injection 300 mcg/0.5 ml contains Filgrastim, a recombinant granulocyte colony-stimulating factor (G-CSF) used to stimulate the production of white blood cells (neutrophils) in the body. It is primarily indicated for patients who are at risk of or experiencing neutropenia, a condition characterized by low neutrophil counts that increases susceptibility to infections.

Filgrastim works by binding to specific receptors on hematopoietic cells in the bone marrow, accelerating the production and maturation of neutrophils. This rapid increase in neutrophil count helps the body fight infections effectively, especially during chemotherapy, bone marrow transplantation, or severe chronic neutropenia.

Grafil is supplied as a pre-filled injection for subcutaneous or intravenous administration, ensuring precise dosing and convenient use in clinical settings.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Grafil Injection 300 mcg/0.5 ml is indicated for:

• Prevention and treatment of chemotherapy-induced neutropenia in cancer patients

• Mobilization of peripheral blood progenitor cells prior to autologous or allogeneic stem cell transplantation

• Severe chronic neutropenia, including congenital, cyclic, or idiopathic forms

• Post-bone marrow transplantation to accelerate neutrophil recovery and reduce infection risk

• Patients undergoing treatments that suppress bone marrow function, requiring support for immune recovery

This makes Grafil a vital supportive therapy for patients undergoing oncology treatment or hematopoietic procedures, where the risk of infection can be life-threatening.

Dosage and Administration

• Adults: The usual dose is 300 mcg per 0.5 ml, administered subcutaneously or intravenously, typically once daily

• The exact dose and duration depend on the patient’s body weight, condition, and physician assessment

• In chemotherapy-induced neutropenia, Grafil is usually administered 24 hours after chemotherapy completion

• For stem cell mobilization, dosing may continue until an adequate number of progenitor cells are collected

• Regular blood counts should be monitored to determine effectiveness and adjust dosing if needed

• Administer under the supervision of trained healthcare personnel, following aseptic techniques

Benefits

• Rapidly increases neutrophil count, reducing the risk of infections

• Supports chemotherapy patients by minimizing treatment interruptions caused by neutropenia

• Enhances immune recovery after bone marrow or stem cell transplantation

• Facilitates stem cell collection for transplantation procedures

• Well-established safety and efficacy profile, supported by clinical research

• Improves overall quality of life for patients vulnerable to infection due to low white blood cell counts

Side Effects

Grafil Injection is generally well tolerated. Common side effects may include:

• Bone pain or mild musculoskeletal discomfort

• Mild fever, headache, or fatigue

• Injection site reactions: redness, swelling, or irritation

• Rare but serious: spleen enlargement or rupture, acute respiratory distress, or allergic reactions

Patients should report persistent bone pain, breathing difficulties, or unusual swelling, as these may require medical attention.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Precautions

• Use with caution in patients with hypersensitivity to Filgrastim or E. coli-derived proteins

• Monitor complete blood counts regularly during therapy

• Caution in patients with a history of splenomegaly or spleen disorders

• Avoid use in conditions where neutrophil proliferation could worsen disease

• Pregnant or breastfeeding women should use only under strict medical supervision

Storage

Store in a refrigerator at 2°C to 8°C, protected from light. Do not freeze. Keep out of reach of children and use only as directed by a healthcare professional.

Grafil Injection 300 mcg/0.5 ml (Filgrastim) is a critical supportive therapy for patients at risk of neutropenia, offering effective neutrophil recovery, infection prevention, and enhanced outcomes during chemotherapy, transplantation, or chronic neutropenia management.